CollPlant Biotechnologies (CLGN) Competitors

$0.42 -0.03 (-6.56%)

Closing price 03:51 PM Eastern

Extended Trading

$0.44 +0.02 (+4.88%)

As of 05:20 PM Eastern

CLGN vs. POAI, RVP, ICCM, OSRH, and ICU

Should you buy CollPlant Biotechnologies stock or one of its competitors? MarketBeat compares CollPlant Biotechnologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CollPlant Biotechnologies include Predictive Oncology (POAI), Retractable Technologies (RVP), IceCure Medical (ICCM), OSR (OSRH), and SeaStar Medical (ICU). These companies are all part of the "medical equipment" industry.

How does CollPlant Biotechnologies compare to Predictive Oncology?

Predictive Oncology (NASDAQ:POAI) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

CollPlant Biotechnologies has a net margin of -353.70% compared to Predictive Oncology's net margin of -5,065.23%. CollPlant Biotechnologies' return on equity of -161.69% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
CollPlant Biotechnologies	-353.70%	-161.69%	-109.44%

Predictive Oncology has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CollPlant Biotechnologies has a consensus price target of $11.50, indicating a potential upside of 2,634.84%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CollPlant Biotechnologies has higher revenue and earnings than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	10.46	-$12.66M	-$13.50	N/A
CollPlant Biotechnologies	$2.37M	2.56	-$11.49M	-$1.35	N/A

In the previous week, Predictive Oncology had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 1 mentions for Predictive Oncology and 0 mentions for CollPlant Biotechnologies. Predictive Oncology's average media sentiment score of 0.75 beat CollPlant Biotechnologies' score of 0.00 indicating that Predictive Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Predictive Oncology	Positive
CollPlant Biotechnologies	Neutral

Summary

CollPlant Biotechnologies beats Predictive Oncology on 13 of the 16 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Retractable Technologies has a net margin of -41.11% compared to CollPlant Biotechnologies' net margin of -353.70%. Retractable Technologies' return on equity of -17.15% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Retractable Technologies	-41.11%	-17.15%	-9.33%
CollPlant Biotechnologies	-353.70%	-161.69%	-109.44%

Retractable Technologies has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

7.6% of Retractable Technologies shares are held by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are held by institutional investors. 59.5% of Retractable Technologies shares are held by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CollPlant Biotechnologies has a consensus target price of $11.50, indicating a potential upside of 2,634.84%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Retractable Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Retractable Technologies has higher revenue and earnings than CollPlant Biotechnologies. Retractable Technologies is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Retractable Technologies	$37.15M	0.54	-$7.01M	-$0.21	N/A
CollPlant Biotechnologies	$2.37M	2.56	-$11.49M	-$1.35	N/A

In the previous week, Retractable Technologies had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 1 mentions for Retractable Technologies and 0 mentions for CollPlant Biotechnologies. Retractable Technologies' average media sentiment score of 0.00 equaled CollPlant Biotechnologies'average media sentiment score.

Company	Overall Sentiment
Retractable Technologies	Neutral
CollPlant Biotechnologies	Neutral

Summary

Retractable Technologies beats CollPlant Biotechnologies on 8 of the 15 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to IceCure Medical?

IceCure Medical (NASDAQ:ICCM) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

IceCure Medical currently has a consensus target price of $2.09, indicating a potential upside of 786.72%. CollPlant Biotechnologies has a consensus target price of $11.50, indicating a potential upside of 2,634.84%. Given CollPlant Biotechnologies' higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than IceCure Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IceCure Medical has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market.

In the previous week, IceCure Medical had 7 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 7 mentions for IceCure Medical and 0 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.00 beat IceCure Medical's score of -0.51 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.

Company	Overall Sentiment
IceCure Medical	Negative
CollPlant Biotechnologies	Neutral

CollPlant Biotechnologies has lower revenue, but higher earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38M	5.67	-$15.06M	-$0.24	N/A
CollPlant Biotechnologies	$2.37M	2.56	-$11.49M	-$1.35	N/A

CollPlant Biotechnologies has a net margin of -353.70% compared to IceCure Medical's net margin of -441.60%. CollPlant Biotechnologies' return on equity of -161.69% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-441.60%	-211.73%	-119.13%
CollPlant Biotechnologies	-353.70%	-161.69%	-109.44%

Summary

CollPlant Biotechnologies beats IceCure Medical on 10 of the 16 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to OSR?

CollPlant Biotechnologies (NASDAQ:CLGN) and OSR (NASDAQ:OSRH) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

CollPlant Biotechnologies currently has a consensus price target of $11.50, suggesting a potential upside of 2,634.84%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, equities analysts plainly believe CollPlant Biotechnologies is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CollPlant Biotechnologies has higher earnings, but lower revenue than OSR. OSR is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.56	-$11.49M	-$1.35	N/A
OSR	$2.91M	6.15	-$27.06M	-$0.33	N/A

In the previous week, CollPlant Biotechnologies' average media sentiment score of 0.00 equaled OSR'saverage media sentiment score.

Company	Overall Sentiment
CollPlant Biotechnologies	Neutral
OSR	Neutral

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by company insiders. Comparatively, 60.6% of OSR shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

CollPlant Biotechnologies has a net margin of -353.70% compared to OSR's net margin of -363.26%. OSR's return on equity of -7.24% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-353.70%	-161.69%	-109.44%
OSR	-363.26%	-7.24%	-5.41%

CollPlant Biotechnologies has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, OSR has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Summary

CollPlant Biotechnologies and OSR tied by winning 7 of the 14 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to SeaStar Medical?

CollPlant Biotechnologies (NASDAQ:CLGN) and SeaStar Medical (NASDAQ:ICU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by insiders. Comparatively, 0.7% of SeaStar Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, SeaStar Medical had 2 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 2 mentions for SeaStar Medical and 0 mentions for CollPlant Biotechnologies. SeaStar Medical's average media sentiment score of 0.36 beat CollPlant Biotechnologies' score of 0.00 indicating that SeaStar Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
CollPlant Biotechnologies	Neutral
SeaStar Medical	Neutral

CollPlant Biotechnologies presently has a consensus target price of $11.50, suggesting a potential upside of 2,634.84%. SeaStar Medical has a consensus target price of $8.00, suggesting a potential upside of 102.02%. Given CollPlant Biotechnologies' higher probable upside, equities analysts plainly believe CollPlant Biotechnologies is more favorable than SeaStar Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CollPlant Biotechnologies has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, SeaStar Medical has a beta of -1.04, meaning that its share price is 204% less volatile than the broader market.

CollPlant Biotechnologies has a net margin of -353.70% compared to SeaStar Medical's net margin of -828.62%. SeaStar Medical's return on equity of -146.29% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-353.70%	-161.69%	-109.44%
SeaStar Medical	-828.62%	-146.29%	-96.48%

CollPlant Biotechnologies has higher revenue and earnings than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.56	-$11.49M	-$1.35	N/A
SeaStar Medical	$1.23M	12.88	-$12.15M	-$4.80	N/A

Summary

CollPlant Biotechnologies beats SeaStar Medical on 9 of the 14 factors compared between the two stocks.

Get CollPlant Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLGN vs. The Competition

Export

Metric	CollPlant Biotechnologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.06M	$3.36B	$6.34B	$12.29B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-0.31	19.01	20.94	25.48
Price / Sales	2.56	278.84	521.14	73.34
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	0.88	6.90	9.98	7.00
Net Income	-$11.49M	$24.23M	$3.55B	$335.16M
7 Day Performance	0.19%	0.59%	0.42%	-0.29%
1 Month Performance	9.51%	-0.61%	-0.05%	1.15%
1 Year Performance	-78.76%	63.26%	35.06%	34.79%

CollPlant Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLGN CollPlant Biotechnologies	1.8249 of 5 stars	$0.42 -6.6%	$11.50 +2,634.8%	-77.3%	$6.06M	$2.37M	N/A	70
POAI Predictive Oncology	0.2128 of 5 stars	$6.66 +17.5%	N/A	-71.2%	$22.60M	$1.66M	N/A	30	Gap Up
RVP Retractable Technologies	N/A	$0.70 +2.4%	N/A	-6.6%	$20.96M	$38.27M	N/A	240	News Coverage
ICCM IceCure Medical	2.8102 of 5 stars	$0.24 flat	$2.64 +997.9%	-76.9%	$19.48M	$3.38M	N/A	60	Gap Down
OSRH OSR	0.419 of 5 stars	$0.64 +13.1%	N/A	-56.5%	$18.81M	$2.91M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLGN) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. POAI, RVP, ICCM, OSRH, and ICU

How does CollPlant Biotechnologies compare to Predictive Oncology?

Summary

How does CollPlant Biotechnologies compare to Retractable Technologies?

Summary

How does CollPlant Biotechnologies compare to IceCure Medical?

Summary

How does CollPlant Biotechnologies compare to OSR?

Summary

How does CollPlant Biotechnologies compare to SeaStar Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. POAI, RVP, ICCM, OSRH, and ICU

How does CollPlant Biotechnologies compare to Predictive Oncology?

Is POAI or CLGN more profitable?

Which has more risk & volatility, POAI or CLGN?

Do institutionals & insiders have more ownership in POAI or CLGN?

Do analysts recommend POAI or CLGN?

Which has stronger earnings & valuation, POAI or CLGN?

Does the media prefer POAI or CLGN?

Summary

How does CollPlant Biotechnologies compare to Retractable Technologies?

Is RVP or CLGN more profitable?

Which has more volatility & risk, RVP or CLGN?

Do institutionals & insiders have more ownership in RVP or CLGN?

Do analysts prefer RVP or CLGN?

Which has preferable valuation and earnings, RVP or CLGN?

Does the media favor RVP or CLGN?

Summary

How does CollPlant Biotechnologies compare to IceCure Medical?

Do insiders & institutionals believe in ICCM or CLGN?

Do analysts prefer ICCM or CLGN?

Which has more volatility & risk, ICCM or CLGN?

Does the media prefer ICCM or CLGN?

Which has better earnings and valuation, ICCM or CLGN?

Is ICCM or CLGN more profitable?

Summary

How does CollPlant Biotechnologies compare to OSR?

Do analysts prefer CLGN or OSRH?

Which has stronger valuation and earnings, CLGN or OSRH?

Does the media refer more to CLGN or OSRH?

Do insiders and institutionals believe in CLGN or OSRH?

Is CLGN or OSRH more profitable?

Which has more volatility and risk, CLGN or OSRH?

Summary

How does CollPlant Biotechnologies compare to SeaStar Medical?

Do insiders & institutionals hold more shares of CLGN or ICU?

Does the media refer more to CLGN or ICU?

Do analysts recommend CLGN or ICU?

Which has more risk and volatility, CLGN or ICU?

Is CLGN or ICU more profitable?

Which has better valuation & earnings, CLGN or ICU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools